Patel Chem Specialities reported a 30.6% year-on-year rise in revenue to ₹1,372.6 crore for the financial year ended March 31, 2026. Net profit increased by 18.7% to ₹125.5 crore, supported by strong domestic demand and the successful completion of its initial public offering.

The Ahmedabad-based manufacturer of pharmaceutical excipients saw its EBITDA grow by 20.1% to ₹188.9 crore. While revenue growth outpaced profit growth, the company maintained healthy operating earnings despite higher capital expenditure on new manufacturing facilities.

Financial Performance

Revenue from operations stood at ₹1,372.6 crore in FY26, compared to ₹1,050.9 crore in the previous year. The top-line expansion was driven by higher business volumes and stronger demand across its product portfolio, including sodium CMC and croscarmellose sodium.

Profit after tax rose from ₹105.7 crore to ₹125.5 crore. The pace of net profit growth remained moderated relative to revenue growth, reflecting the impact of increased operational scale and investments in infrastructure.

What the Numbers Show

EBITDA margin contracted to 13.6% in FY26 from 15.0% in FY25. This divergence between robust revenue growth and margin compression suggests that cost of materials or operating expenses grew faster than sales during the period. Despite the margin dip, absolute operating earnings improved significantly, indicating that volume leverage partially offset the efficiency drag.

Capital Raise and Expansion

The company listed on the BSE SME platform in August 2025, raising ₹58.8 crore through a fresh issue of 70 lakh shares at ₹84 per share. The IPO proceeds are being utilized primarily for capital expenditure, including a new manufacturing facility in Mehsana, Gujarat.

As of March 31, 2026, approximately ₹36.2 crore of the IPO proceeds remained unutilised and was parked in fixed deposits. The company has also completed the expansion of its Talod plant, increasing annual production capacity from 720 MT to 4,500 MT.

Balance Sheet Signals

Net worth surged to ₹995.0 crore from ₹354.0 crore in the prior year, driven by the equity infusion from the IPO. The debt-to-equity ratio improved sharply to 0.15 from 0.42, strengthening the financial position. Current assets grew significantly, with cash and cash equivalents rising to ₹365.9 crore from ₹64.1 crore, providing ample liquidity for future capex plans.

Patel Chem Specialities Limited has announced the re-appointment of M/s RTBR & Associates as its Secretarial Auditor for the financial year 2026-27. The decision was taken by the Board of Directors during their meeting held on May 22, 2026, following the recommendation of the Audit Committee. This move is aimed at ensuring continued compliance with the Companies Act, 2013 and the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Appointment Details

The re-appointment of M/s RTBR & Associates is effective from May 22, 2026. The firm brings extensive experience in Secretarial Audit to the role. The disclosure was made to BSE Limited under Regulation 30 of the Listing Regulations.

Key Information

The following table outlines the specific details regarding the appointment:

The company has confirmed that there are no specific relationships to disclose regarding the directors in this context. The intimation was signed by Bhupesh Patel, Managing Director, on May 22, 2026.